Improved glycemic control with eradication of hepatitis C

Improved glycemic control with eradication of hepatitis C

(HealthDay)—For patients with type 2 diabetes, direct-acting antiviral (DAA) treatment of hepatitis C virus (HCV) is associated with improved glycemic control and reduced antidiabetic medication use, according to a study published online June 28 in Diabetes Care.

Justine Hum, M.D., from Portland Veterans Affairs Medical Center in Oregon, and colleagues identified 2,435 with diabetes who underwent interferon-free and ribavirin-free DAA-based antiviral treatment for HCV to examine whether eradication of HCV infection correlates with improved . They compared the average hemoglobin A1c (HbA1c) level and use of antidiabetic medications one year before and after antiviral treatment for patients who achieved and did not achieve sustained virologic response (SVR).

The researchers found that for patients with elevated baseline HbA1c, those who achieved SVR had a greater drop in HbA1c associated with antiviral treatment than those who sustained treatment failure (0.98 versus 0.65 percent; adjusted mean difference, 0.34). Compared with patients who sustained treatment failure, those who achieved SVR had more of a decrease in antidiabetic medication use, especially for use of insulin, which decreased significantly from 41.3 to 38 percent in patients achieving SVR versus an increase from 49.8 to 51 percent in those who sustained .

"These endocrine benefits of SVR provide additional justification for considering in all patients with diabetes," the authors write.


Explore further

Continuous subcutaneous insulin infusion bests injections in T2DM

More information: Abstract/Full Text (subscription or payment may be required)
Journal information: Diabetes Care

Copyright © 2017 HealthDay. All rights reserved.

Citation: Improved glycemic control with eradication of hepatitis C (2017, July 7) retrieved 21 September 2020 from https://medicalxpress.com/news/2017-07-glycemic-eradication-hepatitis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments